Detection of MET and SOX2 amplification by quantitative real-time PCR in non-small cell lung carcinoma

Oncology Letters

Volumn 2, Issue 2, 2011, Pages 257-264

  Cai, Yi Ran ^a   Zhang, Hai Qing ^a   Zhang, Zong De ^a   Mu, Jing ^a   Li, Zi Hui ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

MET gene; Non small cell lung carcinoma; Real time quantitative PCR; SOX2 gene

Indexed keywords

SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR SOX2;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER INVASION; CARCINOGENESIS; CAUSE OF DEATH; FEMALE; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE; REAL TIME POLYMERASE CHAIN REACTION; SMOKING; TUMOR GROWTH; TUMOR VOLUME;

EID: 79551627806     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2010.229     Document Type: Article

References (51)

1. Travis WD, Brambilla E and Muller-Hermelink HK: World Health Organization Classification of Tumours, Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, 2004.
2. Laird AD and Cherrington JM: Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin Investig Drugs 12: 51-64, 2003.
3. Maulik G, Kijima T and Salgia R: Role of receptor tyrosine kinases in lung cancer. Methods Mol Med 74: 113-125, 2003.
4. Lamorte L and Park M: The receptor tyrosine kinases: role in cancer progression. Surg Oncol Clin N Am 10: 271-288, 2001.
5. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21: 2237-2246, 2003.
6. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149-2158, 2003.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132, 2005.
8. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043, 2007.
9. Naldini L, Weidner KM, Vigna E, et al: Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 10: 2867-2878, 1991.
10. Bottaro DP, Rubin JS, Faletto DL, et al: Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251: 802-804, 1991.
11. Birchmeier C, Birchmeier W, Gherardi E and Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925, 2003.
12. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT and Salgia R: Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 13: 41-59, 2002.
13. Cooper CS, Park M, Blair DG, et al: Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311: 29-33, 1984.
14. Chen JT, Lin TS, Chow KC, et al: Cigarette smoking induces overexpression of hepatocyte growth factor in type II pneumocytes and lung cancer cells. Am J Respir Cell Mol Biol 34: 264-273, 2006.
15. Nakamura Y, Niki T, Goto A, et al: c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci 98: 1006-1013, 2007.
16. Tsao MS, Liu N, Chen JR, et al: Differential expression of Met/ hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer 20: 1-16, 1998.
17. Beau-Faller M, Gaub MP, Schneider A, et al: Allelic imbalance at loci containing FGFR, FGF, c-Met and HGF candidate genes in non-small cell lung cancer sub-types, implication for progression. Eur J Cancer 39: 2538-2547, 2003.
18. Smolen GA, Sordella R, Muir B, et al: Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 103: 2316-2321, 2006.
19. Miller CT, Lin L, Casper AM, et al: Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 25: 409-418, 2006.
20. Que J, Luo X, Schwartz RJ and Hogan BL: Multiple roles for Sox2 in the developing and adult mouse trachea. Development 136: 1899-1907, 2009.
21. Gontan C, de Munck A, Vermeij M, Grosveld F, Tibboel D and Rottier R: Sox2 is important for two crucial processes in lung development: branching morphogenesis and epithelial cell differentiation. Dev Biol 317: 296-309, 2008.
22. Park KS, Wells JM, Zorn AM, et al: Transdifferentiation of ciliated cells during repair of the respiratory epithelium. Am J Respir Cell Mol Biol 34: 151-157, 2006.
23. Tsukamoto T, Mizoshita T, Mihara M, et al: Sox2 expression in human stomach adenocarcinomas with gastric and gastric-and- intestinal-mixed phenotypes. Histopathology 46: 649-658, 2005.
24. Li XL, Eishi Y, Bai YQ, et al: Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. Int J Oncol 24: 257-263, 2004.
25. Hussenet T, Dali S, Exinger J, et al: SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One 5: e8960, 2010.
26. Ebright MI, Zakowski MF, Martin J, et al: Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 74: 1640-1647, 2002.
27. Livak KJ, Flood SJ, Marmaro J, Giusti W and Deetz K: Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl 4: 357-362, 1995.
28. Higuchi R, Fockler C, Dollinger G and Watson R: Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology (NY) 11: 1026-1030, 1993.
29. Holland PM, Abramson RD, Watson R and Gelfand DH: Detection of specific polymerase chain reaction product by utilizing the 5'-3' exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA 88: 7276-7280, 1991.
30. Bieche I, Olivi M, Champeme MH, Vidaud D, Lidereau R and Vidaud M: Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. Int J Cancer 78: 661-666, 1998.
31. Beau-Faller M, Ruppert AM, Voegeli AC, et al: MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naive cohort. J Thorac Oncol 3: 331-339, 2008.
32. Turke AB, Zejnullahu K, Wu YL, et al: Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17: 77-88, 2010.
33. Maestrini E, Tamagnone L, Longati P, et al: A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor. Proc Natl Acad Sci USA 93: 674-678, 1996.
34. Comoglio PM and Boccaccio C: The HGF receptor family: unconventional signal transducers for invasive cell growth. Genes Cells 1: 347-354, 1996.
35. De Herdt MJ and Baatenburg de Jong RJ: HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma. Front Biosci 13: 2516-2526, 2008.
36. Go H, Jeon YK, Park HJ, Sung SW, Seo JW and Chung DH: High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol 5: 305-313, 2010.
37. Okuda K, Sasaki H, Yukiue H, Yano M and Fujii Y: Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 99: 2280-2285, 2008.
38. Bean J, Brennan C, Shih JY, et al: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104: 20932-20937, 2007.
39. Cappuzzo F, Marchetti A, Skokan M, et al: Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 27: 1667-1674, 2009.
40. Masui S, Nakatake Y, Toyooka Y, et al: Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol 9: 625-635, 2007.
41. Wicha MS, Liu S and Dontu G: Cancer stem cells: an old idea--a paradigm shift. Cancer Res 66: 1883-1890, 2006.
42. Ben-Porath I, Thomson MW, Carey VJ, et al: An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507, 2008.
43. Chen Y, Shi L, Zhang L, et al: The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 283: 17969-17978, 2008.
44. Biermann K, Heukamp LC, Steger K, et al: Genome-wide expression profiling reveals new insights into pathogenesis and progression of testicular germ cell tumors. Cancer Genomics Proteomics 4: 359-367, 2007.
45. Sholl LM, Long KB and Hornick JL: Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas. Applied immunohistochemistry & molecular morphology: AIMM/official publication of the Society for Applied Immunohistochemistry 18: 55-61, 2010.
46. Hussenet T and du Manoir S: SOX2 in squamous cell carcinoma: amplifying a pleiotropic oncogene along carcinogenesis. Cell Cycle 9, 1480-1486, 2010.
47. Bass AJ, Watanabe H, Mermel CH, et al: SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41: 1238-1242, 2009.
48. Bjorkqvist AM, Husgafvel-Pursiainen K, Anttila S, et al: DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes Chromosomes Cancer 22: 79-82, 1998.
49. Sholl LM, Barletta JA, Yeap BY, Chirieac LR and Hornick JL: Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol 34: 1193-1198, 2010.
50. McCaughan F, Pole JC, Bankier AT, et al: Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer. Am J Respir Crit Care Med 182: 83-91, 2010.
51. Bastide K, Ugolin N, Levalois C, Bernaudin JF and Chevillard S: Are adenosquamous lung carcinomas a simple mix of adenocarcinomas and squamous cell carcinomas, or more complex at the molecular level? Lung Cancer 68: 1-9, 2010.